Jihad G. Youssef

Houston Methodist Research Institute

6670 Bertner Ave

Houston, 77030

United States

  • Houston Methodist Research Institute

SCHOLARLY PAPERS

4

DOWNLOADS
Rank 5,818

SSRN RANKINGS

Top 5,818

in Total Papers Downloads

13,502

SSRN CITATIONS

10

CROSSREF CITATIONS

2

Scholarly Papers (4)

Actions:
Email selected abstracts
1.

VIP in the Treatment of Critical COVID-19 With Respiratory Failure in Patients With Severe Comorbidity: A Prospective Externally-Controlled Trial

Downloads 8,081 ( 1,510)
Citation 2

VIP in the Treatment of Critical COVID-19 With Respiratory Failure in Patients With Severe Comorbidity: A Prospective Externally-Controlled Trial

Number of pages: 13 Posted: 04 Aug 2020 Last Revised: 05 Oct 2021
Jihad G. Youssef, Jonathan Javitt, Philip Lavin, Mukhtar Al-Saadi, Faisal Zahiruddin, Sarah Beshay, Mohammad Bitar, Joseph Kelley and Mohi Sayed
Houston Methodist Research Institute, Johns Hopkins School of Medicine, Boston Biostatistical Research Foundation, Houston Methodist Hospital, Houston Methodist Hospital, Houston Methodist Hospital, Houston Methodist Hospital, Houston Methodist Hospital and Houston Methodist Hospital
Downloads 6,918 (1,928)

Abstract:

Loading...

VIP, Zyesami, vasoactive intestinal peptide, aviptadil, SARS-CoV-2, corona virus, COVID-19, respiratory failure, IL6, ARDS

Rapid Recovery from COVID-19 Respiratory Failure with Comorbidity in 21 Patients Treated with Vasoactive Intestinal Peptide

Number of pages: 10 Posted: 18 Sep 2020
Jihad G. Youssef, Mukthar Al-Saadi, Faisal Zahiruddin, Sarah Beshay, Mohammad Bitar and Jonathan Javitt
Houston Methodist Research Institute, Houston Methodist Hospital, Houston Methodist Hospital, Houston Methodist Hospital, Houston Methodist Hospital and Johns Hopkins School of Medicine
Downloads 1,163 (33,662)
Citation 2

Abstract:

Loading...

VIP, Vasoactive Intestinal Peptide, Aviptadil, COVID-19, SARS-CoV-2, Antiviral

2.

Intravenous Aviptadil Is Associated with Increased Recovery and Survival in Patients with COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial

Number of pages: 17 Posted: 11 May 2021 Last Revised: 10 Aug 2023
Jihad G. Youssef, Richard Lee, Jonathan Javitt, Philip Lavin, Rainer Lenhardt, David J. Park, Javier Perez Fernandez, Melvin Morganroth and Dushyantha Jayaweera
Houston Methodist Research Institute, University of California, Irvine, Johns Hopkins School of Medicine, Boston Biostatistical Research Foundation, University of Louisville School of Medicine, Providence St. Jude Medical Center/St. Joseph Health Care, Medical Director, Critical Care, Oregon Clinic and University of Miami - Miller School of Medicine
Downloads 3,885 (5,193)
Citation 1

Abstract:

Loading...

Aviptadil, COVID-19, Respiratory Failure, VIP, Vasoactive Intestinal Peptide, ZYESAMI

3.

VIP: A COVID-19 Therapeutic that Blocks Coronavirus Replication

Number of pages: 9 Posted: 12 Aug 2020 Last Revised: 29 Oct 2020
Jonathan Javitt and Jihad G. Youssef
Johns Hopkins School of Medicine and Houston Methodist Research Institute
Downloads 1,223 (31,835)
Citation 4

Abstract:

Loading...

VIP, Aviptadil, COVID-19, coronavirus, SARS-CoV-2, viral replication, cytokine, surfactant, calu-3

4.

Treatment of Sepsis-related Acute Respiratory Distress Syndrome with Vasoactive Intestinal Peptide

Number of pages: 11 Posted: 07 Aug 2020 Last Revised: 19 Aug 2020
Jihad G. Youssef, Sami Said, George Youssef, Matthew J. Javitt and Jonathan Javitt
Houston Methodist Research Institute, State University of New York (SUNY), Stony Brook (desceased), University of Houston, New York University (NYU) - NYU Langone Health and Johns Hopkins School of Medicine
Downloads 313 (178,292)
Citation 4

Abstract:

Loading...

ARDS, VIP, Aviptadil, RLF-100, Acute Respiratory Distress Syndrome, Sepsis